Improved stroke prevention in atrial fibrillation after the introduction of non–vitamin K antagonist oral anticoagulants: the Stockholm experience T Forslund, JJ Komen, M Andersen, B Wettermark, M von Euler, ... Stroke 49 (9), 2122-2128, 2018 | 79 | 2018 |
Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis J Komen, T Forslund, P Hjemdahl, M Andersen, B Wettermark British Journal of Clinical Pharmacology 83 (3), 642-652, 2017 | 55 | 2017 |
Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk JJ Komen, ER Heerdink, OH Klungel, AK Mantel-Teeuwisse, T Forslund, ... European Heart Journal-Cardiovascular Pharmacotherapy 7 (FI1), f72-f80, 2021 | 41 | 2021 |
Valproic acid utilization among girls and women in Stockholm: impact of regulatory restrictions L Karlsson Lind, J Komen, B Wettermark, M von Euler, T Tomson Epilepsia Open 3 (3), 357-363, 2018 | 31 | 2018 |
Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries JJ Komen, A Pottegård, AK Mantel-Teeuwisse, T Forslund, P Hjemdahl, ... EP Europace 23 (11), 1722-1730, 2021 | 29 | 2021 |
The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations I Eriksson, J Komen, F Piehl, RE Malmström, B Wettermark, M von Euler European journal of clinical pharmacology 74, 663-670, 2018 | 26 | 2018 |
Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study JJ Komen, A Pottegård, AK Mantel-Teeuwisse, T Forslund, P Hjemdahl, ... European Heart Journal 43 (37), 3528-3538, 2022 | 25 | 2022 |
Eliminated patient fee and changes in dispensing patterns of asthma medication in children—an interrupted time series analysis E Dahlén, J Komen, EW Jonsson, C Almqvist, I Kull, B Wettermark Basic & clinical pharmacology & toxicology 125 (4), 360-369, 2019 | 23 | 2019 |
Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs J Komen, T Forslund, P Hjemdahl, B Wettermark European Journal of Clinical Pharmacology 73, 1315-1322, 2017 | 18 | 2017 |
Association of preceding antithrombotic therapy in atrial fibrillation patients with ischaemic stroke, intracranial haemorrhage, or gastrointestinal bleed and mortality JJ Komen, T Forslund, AK Mantel-Teeuwisse, OH Klungel, M von Euler, ... European Heart Journal-Cardiovascular Pharmacotherapy 7 (1), 3-10, 2021 | 17 | 2021 |
Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds J Komen, A Pottegård, P Hjemdahl, AK Mantel-Teeuwisse, B Wettermark, ... Heart 108 (8), 613-618, 2022 | 12 | 2022 |
Concomitant anticoagulant and antidepressant therapy in atrial fibrillation patients and risk of stroke and bleeding JJ Komen, P Hjemdahl, AK Mantel‐Teeuwisse, OH Klungel, B Wettermark, ... Clinical Pharmacology & Therapeutics 107 (1), 287-294, 2020 | 12 | 2020 |
Greedy caliper propensity score matching can yield variable estimates of the treatment‐outcome association—A simulation study JJ Komen, SV Belitser, R Wyss, S Schneeweiss, AC Taams, ... Pharmacoepidemiology and drug safety 30 (7), 934-951, 2021 | 8 | 2021 |
Comparative effectiveness and safety of direct oral anticoagulants versus warfarin in UK patients with atrial fibrillation and type 2 diabetes: A retrospective cohort study F Rustem Gulluoglu, PC Souverein, HA van den Ham, A de Boer, ... Pharmacoepidemiology and Drug Safety 30 (10), 1293-1320, 2021 | 4 | 2021 |
1458 Improved stroke prevention in atrial fibrillation after the introduction of NOACs; the Stockholm experience T Forslund, JJ Komen, M Andersen, B Wettermark, M Von Euler, ... European Heart Journal 39 (suppl_1), ehy565. 1458, 2018 | 3 | 2018 |
The association between dyslipidaemia treatment and the risk of clinical events in edoxaban-treated patients with atrial fibrillation: insights from the 2-year follow-up of … TAC De Vries, L Pecen, JJ Komen, JR De Groot, P Kirchhof, ... European Heart Journal 43 (Supplement_2), ehac544. 618, 2022 | 2 | 2022 |
Heterogeneity after harmonisation: A retrospective cohort study of bleeding and stroke risk after the introduction of direct oral anticoagulants in four Western European countries JJ Komen, NB Hunt, A Pottegård, P Hjemdahl, B Wettermark, M Olesen, ... Pharmacoepidemiology and drug safety 32 (11), 1223-1232, 2023 | 1 | 2023 |
Long-term adherence and persistence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk J Komen, R Heerdink, O Klungel, A Mantel-Teeuwisse, T Forslund, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 29, 648-649, 2020 | 1 | 2020 |
Concomitant oral anticoagulant and antidepressant therapy in patients with atrial fibrillation and risk of stroke and bleeding: a population based cohort study JJ Komen, P Hjemdahl, AK Mantel-Teeuwisse, OH Klungel, B Wettermark, ... EUROPEAN HEART JOURNAL 40, 2949-2949, 2019 | 1 | 2019 |
High mortality in atrial fibrillation patients suffering ischemic stroke, intracranial hemorrhage or a gastrointestinal bleed and associations with the preceding antithrombotic … JJ Komen, T Forslund, AK Mantel-Teeuwisse, OH Klungel, B Wettermark, ... EUROPEAN HEART JOURNAL 40, 1848-1848, 2019 | 1 | 2019 |